Rovi earnings call: margins up, growth recalibrated

Laboratorios Farmaceuticos Rovi ((ES:ROVI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Laboratorios Farmacéuticos Rovi’s latest earnings call painted a nuanced picture for investors. Management showcased clear progress on margins, profitability and pipeline, underpinned by strong momentum in flagship drug Okedi and the expanding CDMO business. Yet softer revenues, heparin weakness, higher costs and a more cautious 2026 outlook underscored the near‑term pressures the company must navigate.

Improved profitability and margins

Rovi delivered a notable profitability upgrade despite flat revenues, with gross profit up 5% to EUR 95.0m and gross margin expanding 3.8 points to 62.3%. Excluding other income, gross margin still rose 2.5 points to 60.8%, helped by a richer mix from Okedi, lower heparin raw material costs and higher‑margin CDMO revenue.

CDMO growth and expanding U.S. footprint

Contract manufacturing revenue grew 5% to EUR 37.4m, confirming CDMO as a key strategic pillar even as near‑term growth moderates. The full integration of the Phoenix facility from April 1 strengthens Rovi’s U.S. sterile fill‑and‑finish presence, with a new filling line slated for next year and management still targeting around EUR 700m of CDMO sales by 2030.

Okedi emerges as a leading growth driver

Okedi continued to stand out, posting Q1 sales of EUR 17.2m, up 37% year on year and 10% quarter on quarter. Management emphasized Okedi’s differentiated clinical profile and believes the product can scale to EUR 100m–200m in annual sales over the coming years as uptake broadens across markets.

Pipeline momentum in ISM and R&D

Rovi’s in‑house ISM platform advanced with Letrozole SIE securing FDA IND approval, clearing the way for U.S. clinical development and Phase III recruitment expected in the third quarter of 2026. Risperidone QUAR showed strong Phase I data and is moving into Phase II, while two ongoing Phase III trials reinforce the company’s long‑term innovation credentials.

Solid balance sheet and shareholder payouts

The balance sheet remains healthy, with total debt of EUR 114.4m and gross cash of EUR 99.6m leaving net debt at just EUR 14.9m. Operating cash flow reached EUR 13.0m and free cash flow EUR 5.6m, supporting a 35% payout policy as Rovi plans to propose a dividend of EUR 0.9594 per share against 2025 results.

Revenue softness and tempered near‑term guidance

Despite margin gains, top‑line trends were subdued, with operating revenues slipping 1.5% to EUR 152.5m and total revenues broadly flat at EUR 154.7m. Reflecting these dynamics, management cut its 2026 outlook and now expects only low‑ to mid‑single‑digit operating revenue growth versus 2025, a step down from previous ambitions.

Heparin division under pressure

The heparin franchise, still about 40% of group operating revenue, fell 12% year on year, largely due to lower bemiparin sales amid partner inventory overhang. Management now anticipates low molecular weight heparin sales will decline by a high single‑digit percentage in 2026, facing intensified pricing competition from Chinese players and volatile ordering patterns.

Uncertainty on prefilled syringe CDMO contract

Rovi also reset expectations for its CDMO segment because of delays and reduced demand visibility around a key prefilled syringe manufacturing agreement announced in 2024. Routine manufacturing start‑up and related regulatory timing have slipped, limiting short‑term revenue contribution from a contract that was supposed to be a major growth driver.

Rising operating costs and nonrecurring impacts

Cost inflation weighed on earnings, with SG&A rising 18% to EUR 63.6m on wage adjustments, extra CDMO staffing and higher operating expenses. R&D spend surged 79% to EUR 11.2m in the quarter and is now expected near EUR 60m for the year, while nonrecurring asset write‑offs further pressured the income statement.

Modest cash generation and working capital drag

Cash generation was positive but modest, as operating cash flow of EUR 13.0m was held back by lower profit before tax and adverse working capital movements. Free cash flow of EUR 5.6m, combined with rising investment needs, means near‑term cash flexibility is more limited even though reported net leverage remains low.

Forward‑looking guidance and outlook

Management’s updated guidance centers on modest growth, with 2026 operating revenue now seen rising only a low‑ to mid‑single‑digit percentage versus 2025. While Q1 showed stronger margins, EBITDA of EUR 20.3m and net profit of EUR 9.4m underline the impact of softer heparin trends, revised CDMO timelines and heavier R&D and SG&A, even as the company reiterates long‑term CDMO and Okedi ambitions.

Rovi’s earnings call ultimately balanced caution with conviction, acknowledging near‑term revenue headwinds and cost pressures while highlighting clear structural growth levers in Okedi, CDMO and the ISM pipeline. For investors, the story is one of a specialty pharma group accepting a slower 2026 trajectory as it invests to expand capacity, deepen innovation and build a more diversified earnings base over the medium term.